ClinicalTrials.gg
CompletedNCT00220766Updated Sep 25, 2009

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

A Phase 3 interventional study of Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified and Dextrose, 5% in Water in Immunologic Deficiency Syndrome, Agammaglobulinemia and Severe Combined Immunodeficiency, sponsored by Grifols Therapeutics LLC. Completed at 13 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-09-25.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 127 studies in Immunologic Deficiency Syndromes with a site in United States — 27 open to participants now, 34 under way, none of them phase 3. Immunologic Deficiency Syndromes · United States.

Enrollment
5th of 77
100 · median 28
Started
2002
with 5 others
Phase 3
8 of 127
none open now
Registered
27th of 127
by date
Lead sponsor
3 of 127
Grifols Therapeutics LLC

Among the 127 studies in Immunologic Deficiency Syndromes with a site in United States, this one is the 5th largest by enrollment of the 77 interventional ones that give a count, is one of 6 that started in 2002, is one of 8 in phase 3, and was the 27th registered.

Immunologic Deficiency Syndromes

204 studies on the registry are indexed under Immunologic Deficiency Syndromes; 50 are open to participants now.

Browse Immunologic Deficiency Syndromes studies →

Open to participants now

27 of the 127 studies in Immunologic Deficiency Syndromes with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Immunologic Deficiency Syndromes studies recruiting now, 19 (44%) set no upper age limit and 14 (33%) stop at 75 or younger; 30 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Immunologic Deficiency Syndromes with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to determine if the safety and tolerability of Immune Globulin Intravenous (Human), 10% caprylate/chromatography (IGIV-C)purified is similar when infused at two different infusion rates. The primary objective is to compare the incidence and severity of all infusion related adverse events when IGIV-C, 10% is administered at a rate of 0.14 mL/kg/min compared to a rate of 0.08 mL/kg/min after a single daily infusion.

Read the detailed description

This is a prospective, single blind, randomized, multi-center cross-over trial in patients with Primary Immune Deficiency. Patients with a confirmed diagnosis of primary Immune Deficiency will be treated with two daily infusions given 3-4 weeks apart at the fixed individual IGIV dose regimen (400-600 mg/kg) established prior to entry into the study. Any subject with an established dose in the range of 200-399 mg/kg will be assigned to receive 400 mg/kg during the course of the study during the same dosing schedule established prior to entry into the study.

After a screening period lasting not more than four weeks, patients will be randomized into one of two cross-over groups. Patients randomized to Group 1 will receive their first IGIV-C, 10% dose at a rate of 0.08 mL/kg/min and their second infusion at a rate of 0.14 mL/kg/min, whereas patients randomized to Group 2 will receive IGIV-C, 10% at a rate of 0.14 mL/kg/min on the first infusion day and then 0.08 mL/kg/min on the second infusion day. All patients just prior to each IGIV-C, 10% infusion will receive the same volume of 5% dextrose as calculated for their IGIV-C, 10% infusion and given at a target rate according to the schema below.

Group 1:

  • Infusion #1 (Week 0)Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min)
  • Infusion #2 (Week 3-4)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min)

Group 2:

  • Infusion #1 (Week 0)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min)
  • Infusion #2 Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min)
03

Conditions studied

  • Immunologic Deficiency Syndrome
  • Agammaglobulinemia
  • Severe Combined Immunodeficiency
  • Wiskott-Aldrich Syndrome
  • Common Variable Immunodeficiency

Keywords

  • Primary Immune Deficiency
  • IGIV
  • Immunoglobulin G
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of primary immune deficiency and medical records available for retrospective review for at least 3 months prior to entry into the trial
  • Signed an written informed consent prior to initiation of any study related procedures
  • Receiving regular infusions of IGIV at a fixed interval and dosage (in the range of 200-600 mg/kg given every 3-4 weeks) for at least three months prior to entry into the trial. Patients who are currently receiving less than 400 mg/kg are eligible for this trial and will be at the time of study enrollment be treated at 400 mg/kg

Exclusion criteria

Exclusion Criteria:

  • History or suspicion of significant allergic reaction to intravenous immune globulin, and/or blood products
  • Documented history of selective IgA deficiency (serum level \<5.0 mg/dL) and known antibodies to IgA
  • Isolated IgG subclass deficiency with a normal total serum IgG level
  • Other conditions which may interfere with the trial, include the patients demeanor or mental ability to follow instruction.
  • Pretreatment with anti-pyretics or anti-histamines
  • Congestive heart failure ( stage greater than Class II)
  • Renal insufficiency (creatinine >2.5 mg/dL)
  • Conditions whose symptoms and effects could alter protein catabolism and/or IgG utilization (e.g. protein-losing enteropathies, nephrotic syndrome)
  • Pretreatment routinely required to control/ameliorate IGIV infusion-related adverse events (AEs)
  • Any patient who requires IGIV dosing more frequently than every 3 weeks to maintain adequate trough levels
  • Women of child bearing potential who do not practice adequate (i.e. chemical or mechanical methods) and pregnant or lactating females
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Group 1

    Infusion #1 (Week 0)Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min) ; Infusion #2 (Week 3-4)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min)

    Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified · Drug: Dextrose, 5% in Water

  • Experimental
    Group 2

    Infusion #1 (Week 0)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min); Infusion #2 Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min)

    Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified · Drug: Dextrose, 5% in Water

Interventions

  • DrugImmune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified

    Drug page: Immunoglobulins, Intravenous

    Also known as: Gamunex, IGIVnex, Gaminex, IGIV-C, Immune Globulin Intravenous (Human) , 10%, IGIV, BAY 41-1000, TAL-05-00004

06

What researchers measure

Primary outcomes

  1. Infusion related adverse events

    Time frame: within 72 hours after infusion

Secondary outcomes

  1. All adverse events

    Time frame: within 72 hours after infusion

07

Study locations

13 sites
  • Departments of Medicine and Microbiology
    Birmingham, Alabama 35294, United States
  • National Jewish Medical and Researach Center
    Denver, Colorado 80206, United States
  • International Center for Interdisciplinary Studies of Immunology
    Washington, District of Columbia 20007, United States
  • Allergy Associates of the Palm Beaches
    North Palm Beach, Florida 33408, United States
  • University of South Florida College of Medicine
    St. Petersburg, Florida 33701, United States
  • The Clinical Trials Center, Children's Hospital
    New Orleans, Louisiana 70118, United States
  • Allergy, Asthma, and Immunology
    Omaha, Nebraska 68124, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
  • Optimed Research, LLC
    Columbus, Ohio 43235, United States
  • 3031 Hospital Drive Northwest
    Calgary, Alberta T2N 2T8, Canada
  • St. Paul's Hospital
    Vancouver, British Columbia V6H 3K2, Canada
  • Saint Michael's Hospital
    Toronto, Ontario M4V 1R2, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2002, a primary completion of Aug 2002 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 22, 2005
Start
Aug 2002
Primary completionActual
Aug 2002
CompletionActual
Mar 2004
Last update
Sep 25, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00220766
First posted
Sep 22, 2005
Start date
Aug 2002
Primary completion
Aug 2002
Completion
Mar 2004
Last update
Sep 25, 2009

Study contacts

Erwin Gelfand, MD
principal investigator · National Jewish Medical and Research Center, Denver, CO

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion